Ligand Pharmaceuticals (LGND) Interest Coverage Ratio (2010 - 2026)
Ligand Pharmaceuticals (LGND) reported Interest Coverage Ratio of 1.17 for Q1 2026, up 102.79% on a YoY basis from 0.57 in Q1 2025, and down 62.82% sequentially from 3.13 in Q4 2025.
Ligand Pharmaceuticals (LGND) Interest Coverage Ratio (2010 - 2026) Analysis & Trends
Ligand Pharmaceuticals (LGND) has 17 years of Interest Coverage Ratio data on file, last reported at 1.17 in Q1 2026.
- For the quarter ending Q1 2026, Interest Coverage Ratio rose 102.79% year-over-year to 1.17; the trailing twelve-month figure through Mar 2026 stood at 6.35 (up 138.61% YoY), and the FY2025 full-year result was 1.3, up 509.83% from the prior year.
- Interest Coverage Ratio eased to 1.17 in Q1 2026, from 3.13 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 3078.0 in Q3 2023 to a low of 41.77 in Q1 2025.
- A 5-year average of 183.13 and a median of 3.13 in 2025 frame the typical range for Interest Coverage Ratio.
- Across the five-year window, Interest Coverage Ratio soared 8180.5% in 2023 and tumbled 3196.71% in 2024, its largest moves.
- Tracing LGND's Interest Coverage Ratio over 5 years: stood at 30.45 in 2022, then advanced by 15.83% to 25.63 in 2023, then jumped by 57.42% to 10.91 in 2024, then surged by 128.72% to 3.13 in 2025, then tumbled by 62.82% to 1.17 in 2026.
- Business Quant data shows LGND's Interest Coverage Ratio at 1.17 in Q1 2026, 3.13 in Q4 2025, and 3.69 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 658.42 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 7.60 |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -0.22 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 2.71 |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.72 |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -0.38 |
| 10 | Ligand Pharmaceuticals | 6.05 Bn | 5.27 Bn | 48.45 Mn | 1.17 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.17 |
| Dec 31, 2025 | 3.13 |
| Sep 30, 2025 | 3.69 |
| Jun 30, 2025 | 7.32 |
| Mar 31, 2025 | -41.77 |
| Dec 31, 2024 | -10.91 |
| Sep 30, 2024 | 4.24 |
| Jun 30, 2024 | -15.06 |
| Mar 31, 2024 | 21.19 |
| Dec 31, 2023 | -25.63 |
| Sep 30, 2023 | 3,078.00 |
| Jun 30, 2023 | -0.46 |
| Mar 31, 2023 | 59.19 |
| Dec 31, 2022 | -30.45 |
| Sep 30, 2022 | 37.17 |
| Jun 30, 2022 | 19.78 |
| Mar 31, 2022 | 2.70 |
| Dec 31, 2021 | 2.11 |
| Sep 30, 2021 | 3.54 |
| Jun 30, 2021 | 9.37 |